What the FDA might look like under Donald Trump (and the new Congress)

This article by Melody Peterson explains that a Trump Administration, with the agreement of Congress, may expand a trend in which the Food and Drug Administration cares less about certain drugs' effectiveness than it used to. Here's an excerpt concerning the views of someone Trump is considering to lead the FDA:

One of Trump’s possible selections to head the FDA —  Jim O’Neill, a Silicon Valley venture capitalist with no education in medicine or science —  has raised the idea of approving drugs with no tests of their effectiveness. “Let’s prove efficacy after they’ve been legalized,” O’Neill said in an August 2014 speech at a biotech conference.

Leave a Reply

Your email address will not be published. Required fields are marked *